biologic

Enbrel

etanercept

Loss of exclusivityFebruary 2019projected — 12-year biologic exclusivity estimate
CompanyImmunex Corporation

Drug detail

Brand nameEnbrel
Active ingredientetanercept
Strength25MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2007
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Enbrel patent cliff — loss of exclusivity February 2019 | CliffBio